Actyon – Claim Staking in IP Free Drug Space
Actyon Discovery, Inc. (Actyon) is a new digital drug discovery company focused on the design, validation, and advancement of new drugs based on novel scaffolds from unexplored chemistry.
FreeSpace™ Guided Drug Discovery
Actyon’s FreeSpace™ Platform, employs a proprietary strategy that leverages decades of applied chemical synthesis experience with today’s advanced AI based compound selection and optimization tools.
In silico, we employ expert system based chemical synthesis prediction tools to generate an ultra-large reaction space (ULRS) containing billions of newly conceived synthetically accessible drug-like molecules.
The ULRS is engineered to contain target focused molecules based on novel intellectual property (IP) free scaffolds – FreeSpace™.
Next, we employ AI guided software systems to select and prioritize candidate molecules from this newly created FreeSpace.
Selected candidates are synthesized in wet labs based on reaction strategies provided by the FreeSpace™ Platform. New compounds are tested for biological activity through discovery partners, 3rd party service providers, and when appropriate, internally.
The FreeSpace Advantage: Truly novel synthetically accessible chemistry.
Our FreeSpace™ drug-like chemistry creation approach is reaction site focused enabling it to forecast chemical reactions that generate chemistry beyond known drug-like chemical space. This approach enables Actyon to avoid the limits suffered by generative AI approaches which are constrained to generate concepts within their training sets.